Literature DB >> 26323905

MicroRNA-498 is downregulated in non-small cell lung cancer and correlates with tumor progression.

Mingxi Wang, Qiang Zhang, Junbin Wang, Yunzhi Zhai1.   

Abstract

OBJECTIVE: Non-small cell lung cancer (NSCLC) is the most common type of human lung cancer, with highly aggressive, lethal malignancy and microRNAs have already been proven to be associated with NSCLC tumorigenesis. In this study, we sought to determine the expression, the clinical value and its role in NSCLC tumor progression.
METHODS: Clinical NSCLC tissues and common cell lines were collected. Real-time PCR was performed to quantify the miR-498 expression. In addition, the association of miR-498 expression with clinical pathological factors and prognosis was statistically analyzed. Furthermore, cell proliferation was measured after miR-498 was overexpressed transiently in cells.
RESULTS: We found that miR-498 was significantly decreased in NSCLC tumors as well as cell lines, when compared with their separated controls. Decreased miR-498 expression was associated with sex, tumor type and tumor size. Functionally, ectopic expression of miR-498 in A549 and H661 cells inhibited cell proliferation.
CONCLUSION: Our data indicated that miR-498 is downregulated and correlated with tumor progression, which might be a putitive therapeutic target in NSCLC treatment.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26323905     DOI: 10.4103/0973-1482.163859

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  14 in total

1.  Upregulating microRNA-498 inhibits gastric cancer proliferation invasion and chemoresistance through inverse interaction of Bmi1.

Authors:  Tiancheng Zhao; Yahong Chen; Shihou Sheng; Yuanyu Wu; Tao Zhang
Journal:  Cancer Gene Ther       Date:  2018-12-05       Impact factor: 5.987

2.  MicroRNAs associated with inflammation in shoulder tendinopathy and glenohumeral arthritis.

Authors:  Finosh G Thankam; Chandra S Boosani; Matthew F Dilisio; Devendra K Agrawal
Journal:  Mol Cell Biochem       Date:  2017-06-20       Impact factor: 3.396

3.  MicroRNA-498 promotes proliferation and migration by targeting the tumor suppressor PTEN in breast cancer cells.

Authors:  Chengsen Chai; Hong Wu; Benfan Wang; David D Eisenstat; Roger P Leng
Journal:  Carcinogenesis       Date:  2018-09-21       Impact factor: 4.944

Review 4.  Functions of lncRNA DUXAP8 in non-small cell lung cancer.

Authors:  Cui Wu; Wu Song; Zhongnan Wang; Bingmei Wang
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

5.  MiR-613 induces cell cycle arrest by targeting CDK4 in non-small cell lung cancer.

Authors:  Duo Li; Dong-Qiong Li; Dan Liu; Xiao-Jun Tang
Journal:  Cell Oncol (Dordr)       Date:  2016-01-07       Impact factor: 6.730

6.  miR-498 promotes cell proliferation and inhibits cell apoptosis in retinoblastoma by directly targeting CCPG1.

Authors:  Ling Yang; Ning Wei; Li Wang; Xiang Wang; Qing-Huai Liu
Journal:  Childs Nerv Syst       Date:  2017-12-15       Impact factor: 1.475

7.  MicroRNA-125a-3p downregulation correlates with tumorigenesis and poor prognosis in patients with non-small cell lung cancer.

Authors:  Likun Hou; Pei Luo; Yushui Ma; Chengyou Jia; Fei Yu; Zhongwei Lv; Chunyan Wu; Da Fu
Journal:  Oncol Lett       Date:  2017-08-24       Impact factor: 2.967

8.  circFADS2 regulates lung cancer cells proliferation and invasion via acting as a sponge of miR-498.

Authors:  Fucheng Zhao; Yanru Han; Zhenzhou Liu; Zhenxia Zhao; Zhuoran Li; Kui Jia
Journal:  Biosci Rep       Date:  2018-08-31       Impact factor: 3.840

9.  Long non-coding RNA (lncRNA) HOXB-AS3 promotes cell proliferation and inhibits apoptosis by regulating ADAM9 expression through targeting miR-498-5p in endometrial carcinoma.

Authors:  Ying Xing; Xianhua Sun; Feng Li; Xuan Jiang; Afang Jiang; Xiaofan Li; Ruiting Lv; Liwei Shao
Journal:  J Int Med Res       Date:  2021-06       Impact factor: 1.671

Review 10.  Hypoxia and Selective Autophagy in Cancer Development and Therapy.

Authors:  Ioanna Daskalaki; Ilias Gkikas; Nektarios Tavernarakis
Journal:  Front Cell Dev Biol       Date:  2018-09-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.